TickerStat.comRevenue
2010
2012
2013
2014
2022
2023
2024
2025
Eloxx Pharmaceuticals, Inc. (ELOX)
Price$15.00Cached quote
Net income
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2021
2022
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Jun 30 | 2016 · Dec 31 | 2016 · Jun 30 | 2015 · Dec 31 | 2015 · Jun 30 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | $182,229 | $7,819 | $200,000 | — | $140,000 | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $3.1M | $3.6M | $8.6M | $23.7M | $22.9M | $14.6M | $26.3M | $20.5M | $16.4M | $733,661 | $9.0M | $2.2M | $5.8M | $4.6M | $3.3M | $2.1M | $2.6M | $3.7M | $2.6M | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $6.4M | $8.8M | $17.3M | $34.4M | $66.0M | $33.5M | $50.6M | $47.6M | $20.4M | — | $9.8M | — | $6.3M | — | — | $4.7M | $5.6M | — | $5.0M | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$6.4M | −$2.5M | −$17.3M | −$34.4M | −$66.0M | −$33.5M | −$50.6M | −$47.6M | −$20.4M | −$4.6M | −$9.8M | −$11.2M | −$6.3M | −$18.1M | −$9.1M | −$4.7M | −$5.4M | −$7.9M | −$4.8M | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | −38.81% | — | — | — | — | — | — | — | — | — | — | — | — | −5,019.95% | −59,476.92% | −2,705.76% | — | −3,461.80% | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$6.4M | −$2.4M | −$17.2M | −$34.3M | −$65.9M | −$33.4M | −$50.5M | −$47.3M | −$20.4M | −$4.5M | −$9.8M | −$11.1M | −$6.3M | −$17.9M | −$8.8M | −$4.4M | −$5.2M | −$7.8M | −$4.7M | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | — | −38.26% | — | — | — | — | — | — | — | — | — | — | — | — | −4,828.07% | −55,721.59% | −2,576.75% | — | −3,371.40% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$6.0M | −$3.1M | −$17.1M | −$36.1M | −$66.7M | −$34.6M | −$50.9M | −$47.2M | −$21.2M | −$5.8M | −$9.8M | −$8.3M | −$6.4M | −$18.1M | −$9.2M | −$6.1M | −$5.1M | −$7.3M | −$13.4M | −$5.7M | −$4.6M | −$3.3M | −$3.3M | −$3.0M | −$3.7M | −$2.8M | −$3.0M | −$2.0M | −$3.3M | −$1.2M |
| Net profit margin | — | −49.43% | — | — | — | — | — | — | — | — | — | — | — | — | −5,062.44% | −78,303.39% | −2,533.07% | — | −9,559.65% | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$5.39 | -$9.24 | -$72.93 | -$183.15 | -$419.65 | -$378.40 | -$589.60 | -$638.00 | -$2,090.00 | -$118.80 | -$1,144.00 | -$184.80 | $734.80 | -$576.40 | -$1,113.20 | -$2,248.40 | -$3,520.00 | -$6,160.00 | -$29,480.00 | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$5.39 | -$9.24 | -$72.93 | -$183.15 | -$419.65 | -$378.40 | -$589.60 | -$638.00 | -$2,090.00 | -$118.80 | -$1,144.00 | -$184.80 | $734.80 | -$576.40 | -$1,113.20 | -$2,248.40 | -$3,520.00 | -$6,160.00 | -$29,480.00 | — | — | — | — | — | — | — | — | — | — | — |
Insider buys & sells
Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...